Artículo
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Autor/es | Caballero Velázquez, Teresa
Calderón Cabrera, Cristina López-Corral, L. Puig, N. Marquez-Malaver, F. Pérez-López, E. Pérez Simón, José Antonio |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2020 |
Fecha de depósito | 2024-02-08 |
Publicado en |
|
Resumen | This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, ... This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days -9 and -2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day -5 and tacrolimus (Tk) from -3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2-4 and 3-4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD. |
Agencias financiadoras | Celgene Janssen Ministerio de Sanidad y Politica Social Ministerio de Sanidad y Politica Social, convocatoria de concesion de ayudas para el fomento de la investigacion clinica independiente 2010 Ministry of Health CIBER ONC CB16/12/00480 |
Identificador del proyecto | CM10/00161
EC10-289 |
Cita | Caballero Velázquez, T., Calderón Cabrera, C., López-Corral, L., Puig, N., Marquez-Malaver, F., Pérez-López, E. y Pérez Simón, J.A. (2020). Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 55 (2), 419-430. https://doi.org/10.1038/s41409-019-0670-6. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Efficacy of bortezomib to intensify ... | 745.5Kb | [PDF] | Ver/ | |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.